Last reviewed · How we verify
NCT06547099: SUNBIRD
Blood Amyloid, Tau, and Neurodegeneration Biomarkers and Prediction of Clinical Onset, Cognitive Decline, and Dementia Diagnosis
trial testing Clinical tau PET in Alzheimer Disease in 1,800 participants. Currently enrolling.
1 December 2028
Quick facts
| Lead sponsor | Washington University School of Medicine |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,800 |
| Start date | 14 August 2024 |
| Primary completion | 1 December 2028 |
| Estimated completion | 1 December 2028 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Clinical tau PET
- Clinical amyloid test
- Research blood collection
- Cognitive assessments
Conditions studied
- Alzheimer Disease — all drugs for Alzheimer Disease →
- Mild Cognitive Impairment — all drugs for Mild Cognitive Impairment →
- Dementia — all drugs for Dementia →
Sponsor
Washington University School of Medicine
Who can join
60 and older, any sex, with Alzheimer Disease or Mild Cognitive Impairment. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Area under the curve (AUC) of plasma amyloid-beta 42/40 in predicting amyloid PET status
Time frame: Baseline -
Area under the curve (AUC) of plasma %p-tau217 in predicting amyloid PET status
Time frame: Baseline -
Area under the curve (AUC) of plasma p-tau217 in predicting tau PET status
Time frame: Baseline -
Area under the curve (AUC) of plasma p-tau205 in predicting tau PET status
Time frame: Baseline -
Area under the curve (AUC) of plasma neurofilament light in predicting tau PET status
Time frame: Baseline -
Area under the curve (AUC) of plasma %p-tau205 in predicting clinical diagnosis
Time frame: Baseline, 1 year, 2 years, 3 years, 4 years, 5 years
Sponsor's own description
The purpose of this study is to determine the relationships between amyloid, tau, and neurodegeneration biomarkers in the blood and the presence of Alzheimer's disease (AD) pathology, clinical cognitive decline, and diagnosis. We aim to understand how well blood-based biomarkers can diagnose and predict Alzheimer's disease, which will help to further develop and validate blood tests for the disease.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06547099
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Alzheimer Disease
Currently open trials in the same condition.
- NCT07290387 — Tele-Savvy for Latino Caregivers · NA · recruiting
- NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease · NA · recruiting
- NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease · NA · recruiting
- NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) · Phase 3 · recruiting
- NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting
Other Washington University School of Medicine trials
Trials by the same sponsor.
- NCT05521997 — Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer · Phase 2 · not yet recruiting
- NCT07101666 — Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer · Phase 2 · not yet recruiting
- NCT07200089 — Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) · Phase 1 · not yet recruiting
- NCT07313592 — Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients · not yet recruiting
- NCT07419464 — 5-Fluorouracil Response and Optimization STudy (The FROST Trial) · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06547099 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Washington University School of Medicine
- Last refreshed: 15 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06547099.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing